Terri L. Parker

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji Kumar, Susanna Jacobus, Adam D. Cohen et al. · The Lancet Oncology · 2020 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie et al. · JCI Insight · 2019 · 168 citations · Full text

Life Sciences, Immunology, Oncology +17

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, David Dingli, Robert F. Cornell et al. · Journal of Clinical Oncology · 2018 · 162 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Radiological classification of optic pathway gliomas: experience of a modified functional classification system

Terrie E. Taylor, T. Jaspan, Giuseppe Maria Milano et al. · British Journal of Radiology · 2008 · 141 citations · Full text

Medicine, Neurology, Oncology +15